Medford N.Y USA/Strasbourg France – June 17, 2025 – Chembio Diagnostic Systems, Inc., a subsidiary of Biosynex, developer and manufacturer of rapid diagnostic tests, announced today that the U.S. Food…
Chembio Diagnostics Inc., a subsidiary of Biosynex, receives a grant for Development of a DPP Congenital Syphilis Assay Medford N.Y USA/Strasbourg France , Oct 23, 2024 Chembio Diagnostics, Inc. (Chembio), a…
Chembio Diagnostics, Inc. becomes the first North American structure controlled by Biosynex in North America STRASBOURG, France, April 27, 2023 (GLOBE NEWSWIRE) -- Biosynex SA (“Biosynex”) (EPA: ALBIO), a French market…
MEDFORD, N.Y., Feb. 24, 2023 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced receipt of a Clinical Laboratory Improvement Amendments (CLIA) waiver from the U.S.…
